Breast Cancer Market Size, Share, and Trends

Breast Cancer Market (By Therapy: Targeted Therapy, Hormonal Therapy, Surgery and radiation therapy, Biologic therapy; By Cancer Type: Hormone Receptor, HER2+; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

  • Last Updated : July 2023
  • Report Code : 2396
  • Category : Healthcare

The global breast cancer market size was estimated at USD 28.8 billion in 2022 and is projected to hit around USD 73.68 billion by 2032 with a registered CAGR of 9.9% during the forecast period 2023 to 2032.

Breast Cancer Market Size 2023 To 2032

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Key Takeaways

  • By therapy, the targeted therapy segments involved the largest market.
  • By cancer type, the hormone receptor segments extend the market share at the largest rate.
  • By distribution channel, the hospital pharmacies segments developed their own pharmacies in the hospital with the highest market share.
  • By geography, The North American region holds the highest position in the market with increased market share.

Breast cancer is the most commonly occurring disorder among the population majorly seen in females with rising disorder. Breast cancer is mostly developed in the tissues of the breast. Symptoms of breast cancer are the formation of lumps in the breast, size and shape difference of the breast, fluid coming out of the nipple, and irritating, scaly, red patches on the skin. It is a disorder that spreads the disease with increasing symptoms such as pain in the bones swelling of lymph nodes, breathing problems, and many more.

Breast cancer development takes place with the presence of genes like Human Epidermal growth factor receptor 2 (HER2). Stimulation of cancer in the body with the presence of this protein extends the proliferation of the cells. Positive HER2 receptor patients having the most aggression in breast cancer than other types of breast cancer. Numerous treatments are available which are used to treat and eradicate the tumor and increase the target on HER2. Which enlarges the market of Breast cancer with an increasing number of patients every year with an increase in the recovery rate of breast cancer. 

Enhance research and development with increased new technologies and therapies developed in breast cancer which is prominently contributing to enhancing the market growth with increased demands from the medical sector for treating the patients with new treatments and medications. Government support with increasing providence for new developments in medications and increased efficiency and efficacy of the treatment and integration of newly developed medications in the medical sector.

The impact of covid-19 on the breast cancer market led to a lengthening of the treatment increased time span between treatments due to the widespread coronavirus and decreased rate of patients visiting the hospital with a reduced market of breast cancer. The post-pandemic situation with an increase in the market with significant development of medications and treatment of cancer with increasing the rate of breast cancer every year and enhanced demands from the customer and medical sector for the medication which helps to grow the breast cancer market.

Growth Factors

Increasing prevalence of breast cancer in females every with increased growth of the breast cancer market with the increased number of medications. Improved methods for diagnosis of breast cancer with developed technologies. Increasing developed technologies in breast cancer with increased efficiency, accuracy, efficacy, reliability, and speed of the results with increased performance of detection of the disorder.

Enhanced features developed for detection of the cancer within less period of time. Cancer is detected at an early stage which helps the patients for faster recovery, the cancerous cell is prevented from spreading to other parts of the body and are treated with the new medications available on the market. Increased screening and imaging of the tumor boost the market for breast cancer.  

Increased in research and development with an increased number of treatments introduced by the key market players in the breast market and increase funding from the key market players for the development of the medications and treatment and increase in research for diagnosis of the disorder with increased efficacy and within less period of time.

Increased support from the government for the integration of new treatments and medication in the health care sector with an increasing number of breast cancer among individuals due to reduced exercise, reduced obesity, increased intake of alcohol, hormone problem, menopause, family history of cancer enlarges market of breast cancer to a larger extend. Enhance benefits from the government with an increased number of policies developed such as reimbursement policies so that common people can take benefit of the treatment which are high in cost. This helps for the expansion of the market in breast cancer with new policies and cost effectivity help to increase the breast cancer market size.

The outbreak of Covid-19 with a reduced market of breast cancer reduced patients visits to the hospitals increased the gap between treatment with increased rules and norms imposed by the government due to the widespread coronavirus and an increase in research vaccine on coronavirus came up with an antimalarial drug that is hydroxychloroquine. Which is also effective in treating coronavirus and helps to encourage the market growth of breast cancer with the increasing prevalence of disorder and enhanced demands fuels the breast cancer market value. 

Breast Cancer Market Scope

Report Coverage Details
Market Size in 2023 USD 31.51 Billion
Market Size by 2032 USD 73.68 Billion
Growth Rate from 2023 to 2032 CAGR of 9.9%
Largest Market North America 
Second Largest Market Asia Pacific 
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered
  • By Therapy
  • By Cancer Type
  • By Distribution Channel
Regions Covered
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

 

Breast Cancer Market Dynamics

Key Market Drivers

  • Increasing breast cancer among the population - The increasing rate of patients with breast cancer is the major factor that drives the market of breast cancer to a larger extent across the regions with an increasing number of medications having maximum efficacy and efficiency in the medications. Improve a number of diagnostic procedures which are increasing in day to day to life for imaging and screening of the disorder with quick results with enhanced accuracy of the procedures expected to drive the breast market to a higher level. Due to increased demands from the medical sector and an increasing number of patients with breast cancer and requirements for efficient treatments for the individual to improve health and extend the life of the individuals these factor helps to boost the market for breast cancer.
  • Enhance advanced technologies developed in treating breast cancer - Major factor that helps to increase the market value is new developing technologies with advanced features developed in treatment with increased efficacy of the treatment. Increased developments of the medications with new launches introduced by the key market players with enhanced performance of the treatments with good output seen in the patients with increased efficacy and effectivity of the medications and developed therapies involved in the treatment help to extend the breast cancer market. 

Key Market Challenges 

  • A side effect of the treatment involved in breast cancer - During the treatment involved in breast cancer such as chemotherapy, medications, and targeted therapy involves various side effects after administration of the medication through different routes. Adverse effects involve such as vomiting, diarrhea, mouth ulcer, skin problems, high blood pressure, gastrointestinal problems, and many more these factors may challenge the market to grow to a larger extent with increasing severe adverse effects that may affect the quality of life and increased weakness among the individual. Immunotherapy and targeted therapy chemotherapy are therapies involved with increased adverse reactions that may alter the market size.
  • High cost of the treatment - The advance developed technologies and therapies involved in treating breast cancer with increased results of the treatment and higher efficacy. With the increasing cost of the advanced therapies involved in treating the disorder. Chemotherapy to be most expensive therapy with the increased cost of the medications involved in the therapy where every individual cannot opt for the chemotherapy due enhance cost which may decline the market with decreased revenue share. 
  • Lack of skill - Enhance technologies developed with increased efficacy such as radiation therapy, and immunotherapy with increased skills for performing the procedure. Lack of skill among the individual may decline in the market.

Key Market Opportunities

  • Increased support from the government - Enhance government with increased initiative in developing the treatments with advanced technologies to improve the patient's health and increasing the providence from the government of various regions in improving the research and development in medication for treating breast cancer. Increased number of policies such as reimbursement so that common people can opt for the treatment and take benefit of the medications and treatments available for improving the quality of the life.
  • Increased research and development - The advanced developments in the medications involved in the treatment of breast cancer. Increasing the number of therapies with increased efficiency and enhanced output of the treatments with good results. Developing chemotherapies for treating breast cancer with the increased market with increasing demands from the medical sector due to the widespread of cancerous cells if not treated in time also affect the other organs of the body. Increased attention from the market due to enhance developments for treating the disorder and increased results. Which is a great opportunity which drives the market.
  • Key market players - The key market players involved in development with continuous research for new drug development for treating breast cancer with increased investment from the key market and introduction of new launches with increased effectivity of the developments help to propel the market.

Therapy Insights

On the basis of therapy, the market of breast cancer with more experienced professionals in therapies involved treatment with advanced developed therapies involved for treating breast cancer with increased demands from the market with rising disorder among the population. Increased research and technology in breast cancer medication with an improved number of treatments available help to grow the market rate share.

Targeted therapy involved in the breast market is the largest market with increased utilization of the therapy due to increased output and enhanced performance with new launches involved in the medications helping to accelerate the market of breast cancer. Targeted therapy drugs are such as Kadcyla, Afinitor, Lynparza, and Zortress. Immunotherapy involved also with a higher market share in the breast market with new regulatory approvals.

Cancer Type Insights

On the basis of cancer type analysis, the market of breast cancer is to extend the market share with the largest rate in the hormone receptor during the forecast period with an increasing number of cases of breast cancer every year with developed treatment with new innovative technologies to treat the disorder. Hormone receptor HER2 declined the market share but new launches in treating breast cancer may enhance the market to grow during the forecast period with an increased CAGR rate of the breast cancer market.

Distribution Channel Insights 

On the basis of distribution channels, hospital pharmacies with the highest market share developed their own pharmacies in the hospital. Due to the increased dependence of the patients on the medications required for chemotherapy. Increased demands from patients for various medications and enhanced availability of the medication in hospital pharmacies help to support the growth of the breast cancer market during the forecast period.

Online pharmacies with the largest market share due to increased software development in the hospital and increased online prescriptions in the hospital which stimulates the market of breast cancer with increased online pharmacies and increased connectivity help to grow the breast cancer market during the forecast period.

Regional Insights

On the basis of geography, North America holds the highest position in the market with an increased market share in breast cancer. Advanced developed technologies in the market with an increased number of treatments available for treating breast cancer with an increasing number of patients helps to propel the market growth with increased government initiative in developing new drug developments and increased efficacy of the medications with increased results help to enhance the market growth.

Breast Cancer Market Share, By Region, 2022 (%)

Increased number of market players with increased investment for new developments and expansion of the breast cancer market size. Asia Pacific to be second highest market share with an increasing number of patients and demands. Europe, Latin America, the Middle East, and Africa are in the process to grow the market.

Recent Developments

  • In the year 2020 September, the Partnership of Natco Pharma with Lupin introduced Lapatinib Tablets, 250mg, in the U.S. after receiving approval for the Abbreviated New Drug Application from the (USFDA) U.S. Federal drug Administration. Natco to be the first industry to the introduction of Lapatinib Tablet with 250mg.
  • In the year 2020 June, the Phesgo combination of pertuzumab, trastuzumab, and Hyaluronidase was developed in the injectable type under the skin for the treatment of breast cancer patients with HER2-positive.

Breast Cancer Market Companies

  • Merck & Co
  • Bristol Myers Squiib
  • Kyowa Kirin
  • Eisai Co.Ltd
  • Sanofi 
  • Pfizer Inc
  • AstraZeneca
  • Novartis AG
  • Eli Lilly and Company
  • Genentech
  • Mylan Laboratories
  • Celltrion
  • Fresenius Kabi
  • Baxter Healthcare Corporation
  • Halozyme Inc
  • GlaxoSmithKline

Segments Covered In The Report

By Therapy

  • Targeted Therapy
    • Abemaciclib
    • Adotrastuzumab Emtansine
    • Everolimus
    • Trastuzumab
    • Ribociclib
    • Palbocicib
    • Pertuzumab
    • Olaparib
    • Others
  • Hormonal Therapy
    • Selective Estrogen Receptor Modulators
    • Aromatase Inhibitors
    • Estrogen Receptor Downregulators
    • Chemotherapy ( Epothiones, Taxanes, Alkylating agents, Anthracyclines, Anti-metabolites)
    • Immunotherapy
  • Surgery and radiation therapy
  • Biologic therapy

By Cancer Type

  • Hormone Receptor
  • HER2+

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global breast cancer market size was accounted at USD 28.8 billion in 2022 and it is expected to reach around USD 73.68 billion by 2032.

The global breast cancer market is poised to grow at a CAGR of 9.9% from 2023 to 2032.

The major players operating in the breast cancer market are Merck & Co, Bristol Myers Squiib, Kyowa Kirin, Eisai Co.Ltd, Sanofi, Pfizer Inc, AstraZeneca, Novartis AG, Eli Lilly and Company, Genentech, Mylan Laboratories, Celltrion, Fresenius Kabi, Baxter Healthcare Corporation, Halozyme Inc, GlaxoSmithKline.

The driving factors of the breast cancer market are the increasing breast cancer among the population and enhance advance technologies developed in treating the breast cancer.

North America region will lead the global breast cancer market during the forecast period 2023 to 2032.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Breast Cancer Market 

5.1. COVID-19 Landscape: Breast Cancer Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Breast Cancer Market, By Therapy

8.1. Breast Cancer Market, by Therapy, 2023-2032

8.1.1 Targeted Therapy

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Hormonal Therapy

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Surgery and radiation therapy

8.1.3.1. Market Revenue and Forecast (2021-2032)

8.1.4. Biologic therapy

8.1.4.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Breast Cancer Market, By Cancer Type

9.1. Breast Cancer Market, by Cancer Type, 2023-2032

9.1.1. Hormone Receptor

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. HER2+

9.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Breast Cancer Market, By Distribution Channel 

10.1. Breast Cancer Market, by Distribution Channel, 2023-2032

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2021-2032)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Breast Cancer Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.1.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.1.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.1.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.2.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.2.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.2.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.2.6.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.2.7.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.3.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.3.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.3.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.3.6.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.3.7.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.4.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.4.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.4.6.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.4.7.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.5.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Therapy (2021-2032)

11.5.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)

Chapter 12. Company Profiles

12.1. Merck & Co

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bristol Myers Squiib

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Kyowa Kirin

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Eisai Co.Ltd

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Sanofi

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Pfizer Inc

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. AstraZeneca

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Novartis AG

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Eli Lilly and Company

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Genentech

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client